The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients.

ABSTRACT:

Purpose of review

The landscape of abdominal organ transplantation has been altered by the emergence of curative direct-acting antiviral agents for hepatitis C. Expansion of the thoracic donor pool to include the hearts and the lungs from hepatitis C-positive donors holds promise to increase available donor organs.

Recent findings

Case reports have documented separate lung and heart transplant patients who acquired, and then were cured of, donor-derived hepatitis C using these newer, more effective therapies. Single sites and national consortia are underway to help make this approach part of the standard-of-care. Pangenotypic therapies may simplify the paradigm.

Summary

Organs from donors with active hepatitis C viremia are likely suitable for transplant as long as th

SUBMITTER: Gottlieb RL 

PROVIDER: S-EPMC5945716 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature